Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diffuse Cutaneous Systemic Sclerosis Clear all
Completed Phase 2 Interventional

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

NCT00016458
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
anti-thymocyte globulin, cyclophosphamide
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Denver, Colorado • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2008 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

NCT02283762
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
MTX-474, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Newport Beach, California • Clearwater, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

NCT03831438
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
AVID200
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 22, 2026, 2:03 AM EDT
Recruiting Phase 1 Interventional

US Zamto-cel Autoimmune Diseases

NCT06708845
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Interventions
zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Not applicable Interventional

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801
View directory record Official record
Conditions
Scleroderma, Keloids, Other Fibrosing Conditions
Interventions
German manufactured UVA1 light emitting device
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT03274076
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Tofacitinib, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Jul 22, 2026, 2:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions
KYV-101, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 22, 2026, 2:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NCT07090226
View directory record Official record
Conditions
Systemic Scleroderma, Diffuse Cutaneous Scleroderma
Interventions
Spatial-frequency domain imaging (SFDI)
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis

NCT02921971
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
SAR156597, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 22, 2026, 2:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

NCT03276923
View directory record Official record
Conditions
Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

NCT01093885
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Ambrisentan
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jul 22, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Active, not recruiting Phase 2 Interventional

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

NCT03630211
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

NCT00442611
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IL1-TRAP, Rilonacept, in Systemic Sclerosis

NCT01538719
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions
Rilonacept, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 22, 2026, 2:03 AM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

NCT00129428
View directory record Official record
Conditions
Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions
UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 22, 2026, 2:03 AM EDT
Active, not recruiting Phase 3 Interventional

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label)
Combination Product · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 2:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

Proof of Biological Activity of SAR100842 in Systemic Sclerosis

NCT01651143
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
SAR100842, Placebo (for SAR100842)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Jul 22, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Fresolimumab In Systemic Sclerosis

NCT01284322
View directory record Official record
Conditions
Diffuse Systemic Sclerosis
Interventions
Fresolimumab
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Jul 22, 2026, 2:03 AM EDT